Sweden Launches Initiative to Establish Center for Cell and Gene Therapy Research – Genetic Engineering & Biotechnology News

Sweden aims to establish a new Center for Advanced Medical Products (CAMP) as part of a SEK 320-million ($36.6-million), 8-year Swedish government initiative to position the country as a leading biologics developer.

Swedish regenerative medicine firm Xintela has been appointed a partner in the 6-year project to establish the CAMP cell and gene therapy research center, with SEK 48 million ($5.5 million) in funding from the countrys innovation agency and research council, Vinnova and Vetenskapsrdet. Xintel said that as one of the CAMP initiative founders, it will work with Swedens universities, research institutes, and with firms including AstraZeneca, GE Healthcare and Pfizer. Xintela will initially act as an advisor for development of the center, but in the longer term expects to benefit from emerging R&D.

It is gratifying that the Swedish government, Vinnova and Vetenskapsrdet acknowledge the huge potential of cell and gene therapy and the strong position that Sweden has in this research field,commented Xintela CEO Evy Lundgren-kerlund. Xintela is one of the companies in Sweden with large development potential in cell therapy, which makes us a natural partner for this project.

In the short term CAMP aims to establish itself as an internationally recognised center for R&D, innovation and clinical practice, and to promote industrial growth and SMEs. Longer-term goals include attracting investment from the global pharmaceutical and biotech sectors.

Xintela is exploiting its XINMARK protein marker technology and XACT (Xintela assay for cell therapy) assay platform to develop an allogeneic mesenchymal stem cell-based therapy for repairing cartilage damage in osteoarthritis, and to progress a tumor-targeting antibody treatment for glioblastoma.

Last month the firm established a collaboration with Germany-based CO.DON, which develops autologous cell therapies for cartilage repair. The firms will work together on the development of Xintelas markers both for a next generation CO.DN cell therapy program and for Xintelas cartilage repair cell therapy product.

Here is the original post:
Sweden Launches Initiative to Establish Center for Cell and Gene Therapy Research - Genetic Engineering & Biotechnology News

ICT halts Ph III brain cancer cell therapy trial due to lack of cash – BioPharma-Reporter.com

ImmunoCellular Therapeutics Ltd has halted a Phase III trial of its brain cancer cell therapy ICT-107 due to a lack of funds and is looking for a buyer or partner for the programme.

The Los Angeles, US-based biotech announced the move on June 21, explaining it is unable at this time to secure sufficient additional financial resources to complete the phase III registration trial of ICT-107.

ImmunoCellular said it is looking for a partner or buyer for the programme adding that the suspension of the phase III registration trial of ICT-107 is expected to reduce the amount of cash used in the Companys operations.

ICT-107 is a dendritic cell (DC) vaccine designed to activate a patients immune system to target six different antigens associated with glioblastoma multiforme, a form of brain cancer.

ThePhase III trial is being conducted at sites in the US, Austria and Canada.

The halt comes weeks after ImmunoCellular Therapeutics signalled its intention to raise funds to allow it to continue the study.

R&D costs

According to a first quarter filing ,ImmunoCellular Therapeutics has cash reserves of $5.3m (4.68m), which is just under half of what it had in reserve this time last year.

The document also revealed the firm spent $5.4m in the quarter, the majority of which was used for R&D.

Supplies of ICT-107 for the trial were produced by Netherlands-based contractor PharmaCell, under an agreement announced in 2015 , andCaladrius subsidiary PCT under an deal signed the same year.

Financial details of the contracts have not been disclosed, althoughImmunoCellular Therapeutics does state in its Q1 filing that it is paying PharmaCell for "manufacturing services."

Similarly, while ImmunoCellular Therapeutics does not provide specifics about itsdeal withPCT, it does is say the contractoris providing manufacturing services for the Phase III ICT-107 trial and for a Phase 1 study of ICT-121, a second cell therapy candidate.

ImmunoCellular Therapeutics is alsopaying PCT monthly fees for the use of a controlled environment room and personnel performing the services.

PharmaCell was acquired by Swiss life sciences supplier Lonza last week .

Read the original post:
ICT halts Ph III brain cancer cell therapy trial due to lack of cash - BioPharma-Reporter.com

Dr Prathap C Reddy: Dr Prathap Reddy on the advantages of cell … – ETHealthworld.com

By Rajesh Barnwal

Apollo Hospitals and RMS REGROW on Monday announced their partnership to offer two new Regenerative Medicine Cell Therapy products -- Ossron and Chondron for bone and cartilage problems, respectively to patients in India. According to RMS REGROW, which claims to be the first Make in India company in Cell Therapy Technology, both the products have received the necessary approval from the Drug Controller General of India (DCGI) and have already been tested on 150 patients, none of whom showed any adverse reaction.

On the sidelines of the occasion, ETHealthworld caught up with Dr Prathap C Reddy, founder-chairman of Apollo Hospitals, to find out more about the new technology. An edited excerpt:

Whats the objective that you seek to achieve through this partnership?

I think one is pride. REGROW has made a product in India, got it certified by DCGI, and given to the people. But the certification is not ordinary. They had to go through tremendous regulatory procedures to find that it is safe. And we know well because we participated in the trial. We know that its a safe and effective product both in the management of cartilage damage as well as osteoporosis. So, I think its a great compliment for REGROW and we are happy Apollo is associated with this and we are going to take it to at least 50 of our hospitals to start with. Its going to be a tremendous advantage for the people because if you want the same thing anywhere in the world it would cost approximately 10-20 times more.

How many patients do you see getting benefits from this technology in the next one year?

I think there is no statistics unfortunately for the people who suffer from the minimal or moderate knee pain. They dont go to a doctor or a hospital and swallow pain killer or anti-inflammatory thing and get along with the work. But sometimes it is troublesome; so, if they come to a doctor and say they realise the injury is minimal or moderate this cell therapy is the best thing. All they (doctors) do is they look at through an arthroscope and see whether the cartilage is damaged. If the cartilage is damaged they will demonstrate it to you how simple it is to take a sample from that and grow the same cells in the lab. It (cell therapy) is not like stem cells. Stem cells would neutralise it to make it what we want out of it. If you want to make bone, it would make bone; if you want to make neuro cell, it would make neuro cell; if you want to make blood cell, it would make blood cell out of that stem cell. But here we are making the same thing, cartilage cell is multiplied and bone cell for arthroplasty is multiplied. I think its a tremendous advantage. The process has been made wonderfully well.

This is certainly a new trend. What other new trends you see in the healthcare sector?

I am one of those who feel from day one, 34 years ago when I got into Apollo saying that we, as Indians, deserve the same thing that anybody else got in the world. So, I started a hospital. We are doing everything thats possible, starting from a bypass surgery, because I am a cardiologist. Today we have done the largest number of transplants -- heart transplants, heart-lung transplants, liver, kidney, pancreatic transplants, intestinal transplants, in all of these we became number one in the world; we overtook the largest centre in the US two years ago.

I think the number is not that important in healthcare; in healthcare, whats most important is what is the safety, whats the outcome, and then naturally for the individual what does it cost? I think we have given the same or better outcomes than the best centres in the world at a fraction of the cost. You take bypass, which costs 100,000 dollars, we charge 2,500 dollars. Kidney transplant procedure, which costs something like one crore rupees, we are doing it for 25 lakh rupees. Now, I am getting Proton (Proton Therapy for Cancer Treatment), which is not available in UK, not available in Australia, in Singapore, Malaysia, Middle East or Africa -- three billion people dont have it. This Proton Therapy System is going to cost me about Rs 900 crore; it has arrived in Chennai and its installation is going on; hopefully, they will give it to me in a years time. Then I will be able to give this to people who dont have to travel abroad and spend one and half or two crores of rupees for the treatment. And mostly it is for children. Philanthropically I am trying to build a trust to treat some poor children.

You mentioned that the new cell therapy treatment would cost about Rs 3-4 lakh. Whats the cost of a typical knee replacement surgery?

A knee replacement would cost somewhere around Rs 8-10 lakh in India. What I compliment not only Apollo but all the good hospitals in India for giving the same outcome at a 10 percent of the international cost.

So apart from affordability, what are the other advantages of this new technology?

The great advantage is that people with minimal or moderate pain, instead of swallowing pills, they can get this done simply and become normal. Thats the advantage.

More here:
Dr Prathap C Reddy: Dr Prathap Reddy on the advantages of cell ... - ETHealthworld.com

Patient with severe burns treated using stem cell therapy – Business Standard

IANS | Mumbai June 23, 2017 Last Updated at 00:16 IST

Raising hopes of new and less painful treatment for burn injuries, a 26-year-old patient with Grade 2 burn injuries was successfully treated using stem cell therapy at a city-based hospital, doctors said on Thursday.

Anand Tiwari suffered burns after accidentally falling in a boiler unit while at work. He sustained Grade 2 and early Grade 3 burns in all parts of the body below his neck.

When admitted to the city based StemRx Bioscience Solutions hospital, he had severe burning sensation and pain all over the body. Blisters and swellings were noticed in many areas of his chest and limbs.

According to doctors, after initial care and stabilisation of the patient, for treatment of burns, a treatment protocol was prepared by Pradeep Mahajan, a regenerative medicine researcher at Stemrx Bioscience Solutions Hospital.

Explaining the treatment procedure, Mahajan said: "This involved the use of growth factors and fibroblasts and collagen based gel. These biological agents stimulate natural healing mechanisms in the body."

"The advantage of these growth factors is that they can be obtained from the patients' own body and hence are safe and effective. Additionally, unlike conventional treatment options, biological agents promote faster recovery," he said.

Under the stem cell therapy, the treatment process has to be repeated continuously so as to get rid of the problem completely and accordingly the procedure was performed.

"During the entire treatment, the patient was not given any closed dressing. He also underwent blood and supplementary fluid transfusion as required to maintain systemic homeostasis," said Mahajan.

He said that changes in the patient were observed as early as two-three days after the initiation of therapy. Drying of superficial burns began and swelling started reducing.

"Gradually, dry crusts started peeling and by the end of the third week, initial healing of most areas was complete. There was no odour or oozing from any wound and he did not complain of pain or burning sensation anymore.

"After a month-long treatment, healthy skin formation is being observed and further healing is progressing at an impressive rate," said Mahajan, adding that in treatment through conventional modalities, it takes more than eight weeks for healing to happen and further several months for patient to be able to regain joint and facial movements.

--IANS

rup/nir

(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)

Raising hopes of new and less painful treatment for burn injuries, a 26-year-old patient with Grade 2 burn injuries was successfully treated using stem cell therapy at a city-based hospital, doctors said on Thursday.

Anand Tiwari suffered burns after accidentally falling in a boiler unit while at work. He sustained Grade 2 and early Grade 3 burns in all parts of the body below his neck.

When admitted to the city based StemRx Bioscience Solutions hospital, he had severe burning sensation and pain all over the body. Blisters and swellings were noticed in many areas of his chest and limbs.

According to doctors, after initial care and stabilisation of the patient, for treatment of burns, a treatment protocol was prepared by Pradeep Mahajan, a regenerative medicine researcher at Stemrx Bioscience Solutions Hospital.

Explaining the treatment procedure, Mahajan said: "This involved the use of growth factors and fibroblasts and collagen based gel. These biological agents stimulate natural healing mechanisms in the body."

"The advantage of these growth factors is that they can be obtained from the patients' own body and hence are safe and effective. Additionally, unlike conventional treatment options, biological agents promote faster recovery," he said.

Under the stem cell therapy, the treatment process has to be repeated continuously so as to get rid of the problem completely and accordingly the procedure was performed.

"During the entire treatment, the patient was not given any closed dressing. He also underwent blood and supplementary fluid transfusion as required to maintain systemic homeostasis," said Mahajan.

He said that changes in the patient were observed as early as two-three days after the initiation of therapy. Drying of superficial burns began and swelling started reducing.

"Gradually, dry crusts started peeling and by the end of the third week, initial healing of most areas was complete. There was no odour or oozing from any wound and he did not complain of pain or burning sensation anymore.

"After a month-long treatment, healthy skin formation is being observed and further healing is progressing at an impressive rate," said Mahajan, adding that in treatment through conventional modalities, it takes more than eight weeks for healing to happen and further several months for patient to be able to regain joint and facial movements.

--IANS

rup/nir

(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)

IANS

http://bsmedia.business-standard.com/_media/bs/wap/images/bs_logo_amp.png 177 22

More here:
Patient with severe burns treated using stem cell therapy - Business Standard

Former Titan Tim Shaw visits Bowling Green for book signing – Bowling Green Daily News

KYZ023>043-045>049-053>057-061>067-070>078-081-082-230900-/O.NEW.KLMK.FF.A.0009.170623T1500Z-170624T1200Z//00000.0.ER.000000T0000Z.000000T0000Z.000000T0000Z.OO/Hancock-Breckinridge-Meade-Ohio-Grayson-Hardin-Bullitt-Jefferson-Oldham-Trimble-Henry-Shelby-Franklin-Scott-Harrison-Spencer-Anderson-Woodford-Fayette-Bourbon-Nicholas-Nelson-Washington-Mercer-Jessamine-Clark-Larue-Marion-Boyle-Garrard-Madison-Butler-Edmonson-Hart-Green-Taylor-Casey-Lincoln-Logan-Warren-Simpson-Allen-Barren-Monroe-Metcalfe-Adair-Russell-Cumberland-Clinton-Including the cities of Lewisport, Hawesville, Hardinsburg, Brandenburg, Hartford, Leitchfield, Elizabethtown, Shepherdsville, Louisville, La Grange, Bedford, Milton, New Castle, Shelbyville, Frankfort, Georgetown, Cynthiana, Taylorsville, Lawrenceburg, Versailles, Lexington, Paris, Carlisle, Bardstown, Springfield, Harrodsburg, Nicholasville, Winchester, Hodgenville, Lebanon, Danville, Lancaster, Richmond, Morgantown, Brownsville, Horse Cave, Greensburg, Campbellsville, Liberty, Stanford, Russellville, Bowling Green, Franklin, Providence, Scottsville, Glasgow, Tompkinsville, Edmonton, Columbia, Jamestown, Burkesville, and Albany118 PM EDT Thu Jun 22 2017 /1218 PM CDT Thu Jun 22 2017/...FLASH FLOOD WATCH IN EFFECT FROM FRIDAY MORNING THROUGH EARLYSATURDAY MORNING...The National Weather Service in Louisville has issued a* Flash Flood Watch for central Kentucky. * From Friday morning through early Saturday morning* A cold front coming in from the northwest will join forces with the remnants of Tropical Storm Cindy to produce widespread rain, possibly heavy.PRECAUTIONARY/PREPAREDNESS ACTIONS...A Flash Flood Watch means that conditions may develop that leadto flash flooding. Flash flooding is a very dangerous situation.You should monitor later forecasts and be prepared to take actionshould Flash Flood Warnings be issued.&&$$

Visit link:
Former Titan Tim Shaw visits Bowling Green for book signing - Bowling Green Daily News

What is sickle cell disease? – Popular Science

On Wednesday, rapper Albert Johnsonbetter known by his stage name Prodigypassed away at the age of 42 from complications of sickle cell disease, an inherited blood disorder he'd had since birth. Though some medications can help those with sickle cell manage their condition, no cure or real treatment exists to combat the disease. And while better care in the United States has extended the lifespan of those with the disease, they often face a lifelong battle with pain, infections, and extreme fatigue.

Sickle cell disease afflicts millions of people worldwide; in the United States alone, about 100,000 live with the blood condition. Someone born with sickle cell disease could only expect to live an average of 14 years in the 1970s, and today the average lifespan still only hits 40 to 50 years.

Sickle cell disease is a term for a group of inherited blood disorders that affect the shape of a persons hemoglobinthe protein found in red blood cells that carries and delivers oxygen to the rest of the body.

In genetic terms, the disease is autosomal recessive. For a person to develop it, they must receive two different abnormal hemoglobin genes, one from their mother and one from their father. A few different types of these abnormal genes exist, but for it to develop into sickle cell disease, one of these irregular genes must be a type called hemoglobin S. If a person receives two hemoglobin S genes, then they develop whats called sickle cell anemia, which is the most common and serious disease in the group.

The disease is so debilitating because hemoglobin is one of the most important proteins in the body. When blood reaches the lungs, its job is to collect and transport oxygen to the rest of your organs, which is crucial for survival. Hemoglobin travels inside red blood cells. These cells are typically disc shaped, a form that allows them to easily maneuver en masse through the narrow twists and turns of blood vessels as they travel through the body. But hemoglobin S is weirdly rod shaped, and because of its large size relative to red blood cells, it forces them to take on this oblong shape as well. When every red blood cell is shaped this way, a bunch of them can get jammed inside a blood vessel, slowing or stopping blood flow and preventing oxygen from getting to vital organs. This lack of oxygen can trigger severe pain throughout the body and causes whats known as a pain crisis, the most common debilitating side effect of the disease. While some people dont experience much pain, if any, in between these episodes, others live with chronic, ongoing pain throughout their lives. Meanwhile, while a healthy body constantly replenishes its red blood cells, sickle shaped red blood cells tend to die more easily and people with sickle cell disease often arent able to keep up with this loss. A lack of red blood cells, known as anemia, can lead to crippling fatigue.

In the United States, and around the world, the disease is more common in people of African descent. One of the main reasons for this is because people with sickle cell disease, and those with just one copy of the sickle cell trait, have a better chance at surviving malaria, which is common in Africa, than those without the trait. While the exact mechanism of this is not completely clear, researchers do know that because the microorganisms that cause malaria reside in red blood cells, the frequent destruction of sickled red blood cells forces the microorganisms out as well. Sickle cell is a textbook example of an evolutionary phenomenon called balancing selection: genes that can cause sickle cell in pairs are much more likely to persist in populations that get some benefit out of a single copy of the genewhich is only the case in regions plagued by malaria. Within those regions, the benefit of one copy of the gene keeps it from being selected out of the population; the devastating effects of two copies of the gene keep it from becoming too commonplace.

There is currently no cure for the disease. People are often given pain medications and blood transfusions to manage the pain crises and lack of oxygen, but theres no way to stop the body from making these poorly-shaped hemoglobin cells.

Some people have tried stem cell transplants, where doctors kill off the abnormal hemoglobin with drugs before infusing patients with blood cells from a donor's bone marrow. Finding a suitable donor is tricky though, and these transplants are especially risky for adults.

However, future treatments may be on the horizon. Because sickle cell disease arises from a mutation in a single gene in a persons DNA, new gene editing technologies such as CRISPR-Cas9, which allows scientists to edit the human genome with relative ease, could perhaps lead to a way to cure the disease. In fact, this past year, researchers at the University of California, Berkeley, published results from a study showing success in using CRISPR to edit out the disease in mice. However, while promising, we're still a long way from the treatment reaching humans. The biggest concern is that the editing technique will alter other areas of the genome that appear similar to the ones that need to be edited outsomething called off-target effects. Researchers still need to understand why these off-target effects occur, and how to prevent them, before this technique can be safely used in humans.

Read more from the original source:
What is sickle cell disease? - Popular Science

There are millions of protein factories in every cell. Surprise, they’re not all the same – Science Magazine

Ribosomes, which build a protein (black) from an RNA strand (blue), may specialize in making particular sets of proteins.

V. ALTOUNIAN/SCIENCE

By Mitch LeslieJun. 21, 2017 , 11:00 AM

The plant that built your computer isn't churning out cars and toys as well. But many researchers think cells' crucial protein factories, organelles known as ribosomes, are interchangeable, each one able to make any of the body's proteins. Now, a provocative study suggests that some ribosomes, like modern factories, specialize to manufacture only certain products. Such tailored ribosomes could provide a cell with another way to control which proteins it generates. They could also help explain the puzzling symptoms of certain diseases, which might arise when particular ribosomes are defective.

Biologists have long debated whether ribosomes specialize, and some remain unconvinced by the new work. But other researchers say they are sold on the finding, which relied on sophisticated analytical techniques. "This is really an important step in redefining how we think about this central player in molecular biology," says Jonathan Dinman, a molecular biologist at the University of Maryland in College Park.

A mammalian cell may harbor as many as 10 million ribosomes, and it can devote up to 60% of its energy to constructing them from RNA and 80 different types of proteins. Although ribosomes are costly, they are essential for translating the genetic code, carried in messenger RNA (mRNA) molecules, into all the proteins the cell needs. "Life evolved around the ribosome," Dinman says.

The standard view has been that a ribosome doesn't play favorites with mRNAsand therefore can synthesize every protein variety. But for decades, some researchers have reported hints of customized ribosomes. For example, molecular and developmental biologist Maria Barna of Stanford University in Palo Alto, California, and colleagues reported in 2011 that mice with too little of one ribosome protein have short tails, sprout extra ribs, and display other anatomical defects. That pattern of abnormalities suggested that the protein shortage had crippled ribosomes specialized for manufacturing proteins key to embryonic development.

Definitive evidence for such differences has been elusive, however. "It's been a really hard field to make progress in," says structural and systems biologist Jamie Cate of the University of California (UC), Berkeley. For one thing, he says, measuring the concentrations of proteins in naturally occurring ribosomes has been difficult.

In their latest study, published online last week in Molecular Cell, Barna and her team determined the abundances of various ribosome proteins with a method known as selected reaction monitoring, which depends on a type of mass spectrometry, a technique for sorting molecules by their weight. When the researchers analyzed 15 ribosomal proteins in mouse embryonic stem cells, they found that nine of the proteins were equally common in all ribosomes. However, four were absent from 30% to 40% of the organelles, suggesting that those ribosomes were distinctive. Among 76 ribosome proteins the scientists measured with another mass spectrometry-based method, seven varied enough to indicate ribosome specialization.

Barna and colleagues then asked whether they could identify the proteins that the seemingly distinctive ribosomes made. A technique called ribosome profiling enabled them to pinpoint which mRNAs the organelles were readingand thus determine their end products. The specialized ribosomes often concentrated on proteins that worked together to perform particular tasks. One type of ribosome built several proteins that control growth, for example. A second type churned out all the proteins that allow cells to use vitamin B12, an essential molecule for metabolism. That each ribosome focused on proteins crucial for a certain function took the team by surprise, Barna says. "I don't think any of us would have expected this."

Ribosome specialization could explain the symptoms of several rare diseases, known as ribosomopathies, in which the organelles are defective. In Diamond-Blackfan anemia, for instance, the bone marrow that generates new blood cells is faulty, but patients also often have birth defects such as a small head and misshapen or missing thumbs. These seemingly unconnected abnormalities might have a single cause, the researchers suggest, if the cells that spawn these different parts of the body during embryonic development carry the same specialized ribosomes.

Normal cells might be able to dial protein production up or down by adjusting the numbers of these specialized factories, providing "a new layer of control of gene expression," Barna says. Why cells need another mechanism for controlling gene activity isn't clear, says Cate, but it could help keep cells stable if their environment changes.

He and Dinman say the use of "state-of-the-art tools" makes the results from Barna's team compelling. However, molecular biologist Harry Noller of UC Santa Cruz doubts that cells would evolve to reshuffle the array of proteins in the organelles. "The ribosome is very expensive to synthesize for the cell," he says. If cells are going to tailor their ribosomes, "the cheaper way to do it" would entail modifying a universal ribosome structure rather than building custom ones.

See the original post:
There are millions of protein factories in every cell. Surprise, they're not all the same - Science Magazine

Extra-virgin olive oil preserves memory and protects brain against Alzheimer’s: study – Medical Xpress

June 21, 2017 Domenico Pratic, MD, Professor in the Departments of Pharmacology and Microbiology and the Center for Translational Medicine at the Lewis Katz School of Medicine at Temple University. Credit: Lewis Katz School of Medicine at Temple University

The Mediterranean diet, rich in plant-based foods, is associated with a variety of health benefits, including a lower incidence of dementia. Now, researchers at the Lewis Katz School of Medicine at Temple University (LKSOM) have identified a specific ingredient that protects against cognitive decline: extra-virgin olive oil, a major component of the Mediterranean diet. In a study published online June 21 in the Annals of Clinical and Translational Neurology, the researchers show that the consumption of extra-virgin olive oil protects memory and learning ability and reduces the formation of amyloid-beta plaques and neurofibrillary tangles in the brainclassic markers of Alzheimer's disease.

The Temple team also identified the mechanisms underlying the protective effects of extra-virgin olive oil. "We found that olive oil reduces brain inflammation but most importantly activates a process known as autophagy," explained senior investigator Domenico Pratic, MD, Professor in the Departments of Pharmacology and Microbiology and the Center for Translational Medicine at LKSOM. Autophagy is the process by which cells break down and clear out intracellular debris and toxins, such as amyloid plaques and tau tangles.

"Brain cells from mice fed diets enriched with extra-virgin olive oil had higher levels of autophagy and reduced levels of amyloid plaques and phosphorylated tau," Dr. Pratic said. The latter substance, phosphorylated tau, is responsible for neurofibrillary tangles, which are suspected of contributing to the nerve cell dysfunction in the brain that is responsible for Alzheimer's memory symptoms.

Previous studies have suggested that the widespread use of extra-virgin olive oil in the diets of people living in the Mediterranean areas is largely responsible for the many health benefits linked to the Mediterranean diet. "The thinking is that extra-virgin olive oil is better than fruits and vegetables alone, and as a monounsaturated vegetable fat it is healthier than saturated animal fats," according to Dr. Pratic.

In order to investigate the relationship between extra-virgin olive oil and dementia, Dr. Pratic and colleagues used a well-established Alzheimer's disease mouse model. Known as a triple transgenic model, the animals develop three key characteristics of the disease: memory impairment, amyloid plagues, and neurofibrillary tangles.

The researchers divided the animals into two groups, one that received a chow diet enriched with extra-virgin olive oil and one that received the regular chow diet without it. The olive oil was introduced into the diet when the mice were six months old, before symptoms of Alzheimer's disease begin to emerge in the animal model.

In overall appearance, there was no difference between the two groups of animals. However, at age 9 months and 12 months, mice on the extra virgin olive oil-enriched diet performed significantly better on tests designed to evaluate working memory, spatial memory, and learning abilities.

Studies of brain tissue from both groups of mice revealed dramatic differences in nerve cell appearance and function.

"One thing that stood out immediately was synaptic integrity," Dr. Pratic said. The integrity of the connections between neurons, known as synapses, were preserved in animals on the extra-virgin olive oil diet. In addition, compared to mice on a regular diet, brain cells from animals in the olive oil group showed a dramatic increase in nerve cell autophagy activation, which was ultimately responsible for the reduction in levels of amyloid plaques and phosphorylated tau.

"This is an exciting finding for us," explained Dr. Pratic. "Thanks to the autophagy activation, memory and synaptic integrity were preserved, and the pathological effects in animals otherwise destined to develop Alzheimer's disease were significantly reduced. This is a very important discovery, since we suspect that a reduction in autophagy marks the beginning of Alzheimer's disease."

Dr. Pratic and colleagues plan next to investigate the effects of introducing extra-virgin olive oil into the diet of the same mice at 12 months of age, when they have already developed plaques and tangles. "Usually when a patient sees a doctor for suspected symptoms of dementia, the disease is already present," Dr. Pratic added. "We want to know whether olive oil added at a later time point in the diet can stop or reverse the disease."

Explore further: Mouse experiment sheds light on the dietary benefits of extra virgin olive oil

Experiments carried out in mice have revealed that a compound commonly found in extra-virgin olive oil can reverse some of the negative effects of a high-fat diet. This compound, called hydroxytyrosol, was able to reverse ...

A Mediterranean diet rich in virgin olive oil may enhance the cardioprotective benefits of high-density lipoproteins (HDLthe "good" cholesterol) compared to other diets, according to new research in the American Heart ...

One of the earliest signs of Alzheimer's disease is a decline in glucose levels in the brain. It appears in the early stages of mild cognitive impairmentbefore symptoms of memory problems begin to surface. Whether it is ...

For people with metabolic syndrome, a Mediterranean diet supplemented with extra-virgin olive oil or nuts may help reverse the condition, indicate findings from a clinical trial published in CMAJ (Canadian Medical Association ...

Researchers at the University of Cambridge have designed antibodies that target the protein deposits in the brain associated with Alzheimer's disease, and stop their production.

A plant extract used for centuries in traditional medicine in Nigeria could form the basis of a new drug to treat Alzheimer's disease, researchers at The University of Nottingham have found.

The rate of death from Alzheimer's disease in the United States increased by more than 50 percent in the past 15 years, according to new data from the Centers for Disease Control and Prevention.

Older adults with elevated levels of brain-clogging plaquesbut otherwise normal cognitionexperience faster mental decline suggestive of Alzheimer's disease, according to a new study led by the Keck School of Medicine ...

A diet high in cholesterol, fat and sugar may influence the development of Alzheimer's disease in people who carry the ApoE4 gene, a leading risk factor for the memory-erasing disease, indicates a new USC study.

A new study by researchers at the University of Montana, Universidad del Valle de Mxico, Instituto Nacional de Pediatra, Boise State, and Universidad Nacional Autnoma de Mxico, heightens concerns over the detrimental ...

Adjust slider to filter visible comments by rank

Display comments: newest first

Extra virgin olive oil's free fatty acids resemble those in human skin surface lipids.

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

View original post here:
Extra-virgin olive oil preserves memory and protects brain against Alzheimer's: study - Medical Xpress

High-fat diet leads to same intestinal inflammation as a virus – UCLA Newsroom

FINDINGS

A new study by scientists at UCLA found that when mice eat a high-fat diet, the cells in their small intestines respond the same way they do to a viral infection, turning up production of certain immune molecules and causing inflammation throughout the body. The scientists also found that feeding the mice tomatoes containing a protein similar to that in HDL, or good cholesterol, along with the generic cholesterol drug Ezetimibe, reversed the inflammation.

The results could lead to new types of drugs, targeting the intestinal cells, to reduce peoples risk of heart attacks and strokes, or to treat other conditions linked to inflammation, including cancer and inflammatory bowel disease.

Researchers already knew that prolonged obesity can cause inflammation of the liver and fat tissues, and that this inflammation contributes to the development of diabetes and heart disease. Studies have also shown that higher levels of high-density lipoprotein, or HDL, cholesterol, reduces a persons risk of heart disease.

The UCLA research team, led by Alan Fogelman, chair of the department of medicine at the David Geffen School of Medicine at UCLA,previously developed genetically engineered tomatoes that contained 6F, a protein resembling the main protein in high-density lipoprotein. In early experiments on 6F, they found that the compound was active in the small intestines of mice, and that it reduced inflammation. But exactly how it did this was unclear.

The scientists fed either a standard chow or a high-fat, high-cholesterol Western diet to mice that were especially prone to developing clogged arteries. They also treated some of the mice with either 6F, in the form of a tomato concentrate containing the protein, Ezetimibe, or both. After two weeks, cells from the small intestines of the mice were collected and blood samples were taken. The researchers measured cholesterol levels as well as the levels of inflammatory and immune molecules in both the intestines and throughout the body.

The findings shed light on the molecular details of how high-fat diets cause inflammation in the body, by making the intestines activate the pathway normally triggered by a virus. This suggests that blocking this immune reaction as 6F and Ezetimibe do may treat inflammatory diseases and decrease peoples risk of heart attack and stroke.

The authors of the study are all faculty and researchers at UCLA, affiliated with the Department of Medicine; Department of Molecular and Medical Pharmacology; Department of Human Genetics; Department of Microbiology, Immunology & Molecular Genetics; Department of Pathology and Laboratory Medicine; Department of Obstetrics and Gynecology; Semel Institute for Neuroscience and Human Behavior; and Department of Molecular, Cell and Developmental Biology. The first author is Pallavi Mukherjee; Fogelman is the senior author.

The studywas published June 7, 2017, in the Journal of Lipid Research.

The study was funded by the United States Public Health Service (2P01 HL-30568) and the Castera, Laubisch, and Milt Grey funds at UCLA.

Alan Fogelman, Mohamad Navab and Srinivasa Reddy are principals in Bruin Pharma, which is working to commercialize apoA-I mimetics, including the 6F peptide studied in this paper; Fogelman is additionally an officer of the company.

Go here to see the original:
High-fat diet leads to same intestinal inflammation as a virus - UCLA Newsroom

Cell Medica boosts manufacturing capacity in cell therapy deal – BioPharma Dive

Dive Brief:

Even more than traditional drug development, manufacturing is a crucial step in the development of complex therapeutics like cell therapies. As the field evolves, it will likely be a difference maker between success and setback. Such focus on production and logistics can be see in the attention paid to the processes set up by the more advanced CAR-T developers like Kite Pharma, Novartis and Juno Therapeutics.

With this deal, Cell Medica has seized on an opportunity to gain access to an existing GMP facility, taking a short cut to support further development and potential commercialization of the WT1-TCR therapy. More cell therapy products might also be produced at the site in the future, Cell Medica said.

Catapult Therapy TCR was created by CGT Catapult, UCL Business and Imperial Innovations the technology transfer arms of University College London and Imperial College, London in order to develop the WT1-TCR cell therapy.

By acquiring Catapult Therapy TCR, Cell Medica can also integrate WT1-TCR cell therapy into its Dominant TCR platform technology. This has potential to improve efficacy, Cell Medica believes, and to expand use of the therapeutic from its existing focus on blood cancers to hard-to-treat solid tumors such as mesothelioma and ovarian cancer.

Cell Medica recently upped its financial firepower,closinga 60 million ($75.9 million) Series C investor round in March 2017 to further develop its cell-based cancer immunotherapies.

Read more here:
Cell Medica boosts manufacturing capacity in cell therapy deal - BioPharma Dive